Cabot (NYSE:CBT) Stock Lifted to “Buy” by Wall Street Zen

Wall Street Zen upgraded shares of Cabot (NYSE:CBT) from a hold rating to a buy rating in a research report report published on Sunday,Wall Street Zen reports.

Several other research firms have also recently weighed in on CBT. Mizuho raised their price target on Cabot from $80.00 to $90.00 and gave the company a “neutral” rating in a report on Thursday, June 25th. JPMorgan Chase & Co. lifted their price target on Cabot from $70.00 to $78.00 and gave the company an “underweight” rating in a research report on Friday, August 7th. Truist Financial set a $100.00 price objective on Cabot in a report on Wednesday, August 5th. Weiss Ratings restated a “hold (c)” rating on shares of Cabot in a research report on Friday, August 21st. Finally, UBS Group decreased their price objective on shares of Cabot from $92.00 to $86.00 and set a “neutral” rating on the stock in a research report on Monday, October 5th. Two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $87.80.

Cabot Stock Up 0.2%

Shares of NYSE:CBT opened at $75.05 on Friday. The firm has a fifty day moving average price of $81.48 and a two-hundred day moving average price of $82.49. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 0.97. Cabot has a one year low of $58.33 and a one year high of $94.53. The company has a market cap of $3.87 billion, a price-to-earnings ratio of 21.14, a PEG ratio of 8.82 and a beta of 0.83.

Cabot (NYSE:CBT) last released its quarterly earnings results on Monday, August 3rd. The specialty chemicals company reported $1.67 EPS for the quarter, beating analysts’ consensus estimates of $1.66 by $0.01. The firm had revenue of $982.00 million during the quarter, compared to analyst estimates of $943.16 million. Cabot had a net margin of 5.23% and a return on equity of 20.29%. The business’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.90 EPS. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. Analysts anticipate that Cabot will post 6.35 EPS for the current fiscal year.

Insider Buying and Selling at Cabot

In related news, CEO Sean Keohane sold 134,895 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $85.00, for a total value of $11,466,075.00. Following the completion of the sale, the chief executive officer owned 404,134 shares in the company, valued at $34,351,390. The trade was a 25.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last 90 days, insiders sold 229,597 shares of company stock worth $19,646,746. Company insiders own 3.08% of the company’s stock.

Institutional Trading of Cabot

Hedge funds and other institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. bought a new stake in Cabot in the second quarter valued at approximately $33,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Cabot by 76.8% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 944 shares of the specialty chemicals company’s stock valued at $63,000 after purchasing an additional 410 shares during the period. Rockefeller Capital Management L.P. grew its holdings in shares of Cabot by 115.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,152 shares of the specialty chemicals company’s stock worth $76,000 after purchasing an additional 617 shares during the last quarter. Global Retirement Partners LLC bought a new position in shares of Cabot in the second quarter worth approximately $88,000. Finally, Parallel Advisors LLC grew its holdings in shares of Cabot by 10.5% in the first quarter. Parallel Advisors LLC now owns 1,843 shares of the specialty chemicals company’s stock worth $139,000 after purchasing an additional 175 shares during the last quarter. Hedge funds and other institutional investors own 93.18% of the company’s stock.

Cabot Company Profile

Cabot Corporation (NYSE: CBT) is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company develops and manufactures materials used by industrial and consumer-product manufacturers worldwide.

Cabot’s products include reinforcing carbon blacks used in tires, automotive components, and other rubber products; specialty carbon blacks used in coatings, plastics, inks, and batteries; and fumed silica used in adhesives, sealants, coatings, and personal-care applications.